Is Crestor Better Than Lipitor? Rosuvastatin vs. Atorvastatin Compared

How the Two Drugs Compare on LDL Reduction

Milligram for milligram, rosuvastatin is the more potent LDL-lowering statin. The STELLAR trial (N=2,431) directly compared the two drugs across their full dose ranges and found that rosuvastatin 10 mg reduced LDL by 46%, while atorvastatin 10 mg reduced it by 37% [1]. At the highest approved doses, rosuvastatin 40 mg achieved a 55% mean LDL reduction compared with 51% for atorvastatin 80 mg.

What the Dose-Equivalency Data Show

A common prescribing shorthand holds that rosuvastatin 10 mg approximates atorvastatin 20 mg in LDL-lowering effect. The 2018 ACC/AHA cholesterol guideline classifies both atorvastatin 40-80 mg and rosuvastatin 20-40 mg as "high-intensity" statin therapy, expected to lower LDL by 50% or more [2]. For most patients who need aggressive LDL lowering, the practical gap between the two drugs narrows at guideline-recommended doses.

Does a Few Percentage Points Matter Clinically?

It can. The CTT Collaborators meta-analysis (N=170,000 across 26 trials) demonstrated that every 1 mmol/L (approximately 39 mg/dL) reduction in LDL translates to a 22% relative reduction in major vascular events over five years [3]. For a patient whose baseline LDL sits at 190 mg/dL, a 5% greater reduction with rosuvastatin could mean an additional 9-10 mg/dL drop. Whether that difference changes hard outcomes depends on total cardiovascular risk, not LDL alone.

HDL and Triglyceride Effects

Rosuvastatin also edges ahead on HDL raising. STELLAR showed rosuvastatin 40 mg increased HDL by 9.6% versus 5.7% with atorvastatin 80 mg [1]. Triglyceride reductions were similar between the two drugs at equipotent doses, both achieving roughly 20-28% reductions at high-intensity levels.

Head-to-Head Cardiovascular Outcome Data

No single randomized controlled trial has compared rosuvastatin and atorvastatin on hard cardiovascular endpoints (heart attack, stroke, cardiovascular death) against each other. The evidence base for each drug comes from separate landmark trials.

Rosuvastatin's Key Trials

The JUPITER trial (N=17,802) randomized patients with LDL <130 mg/dL but elevated high-sensitivity CRP to rosuvastatin 20 mg or placebo. Rosuvastatin reduced the primary composite endpoint of MI, stroke, revascularization, hospitalization for unstable angina, or cardiovascular death by 44% (HR 0.56, 95% CI 0.46-0.69) [4]. The trial was stopped early at a median of 1.9 years because of the clear benefit. This trial established rosuvastatin's role in primary prevention among patients with inflammatory markers.

Atorvastatin's Key Trials

Atorvastatin carries one of the deepest outcome trial portfolios of any statin. The CARDS trial (N=2,838) showed atorvastatin 10 mg reduced major cardiovascular events by 37% in patients with type 2 diabetes [5]. The TNT trial (N=10,001) demonstrated that atorvastatin 80 mg reduced cardiovascular events by 22% compared with atorvastatin 10 mg in stable coronary disease patients [6]. The SPARCL trial (N=4,731) was the first to show a statin (atorvastatin 80 mg) reduced recurrent stroke risk in patients with recent stroke or TIA by 16% [7].

The SATURN Plaque Trial

SATURN (N=1,039) is the closest thing to a direct outcome-adjacent comparison. This trial used intravascular ultrasound to measure coronary atheroma volume after 24 months of treatment with either rosuvastatin 40 mg or atorvastatin 80 mg. Both drugs produced plaque regression. Rosuvastatin achieved a numerically greater reduction in percent atheroma volume (1.22% vs. 0.99%), but the difference was not statistically significant (p=0.17) [8]. Both groups saw similar reductions in total atheroma volume.

Side Effect Profiles

Both drugs belong to the same pharmacological class and share the same core side-effect risks. Muscle symptoms are the most common reason patients stop statins.

Muscle-Related Adverse Events

A 2022 Lancet meta-analysis of 19 large statin trials (N=123,940) found that statins as a class increased muscle pain or weakness reports by only 7% compared with placebo during the first year of therapy [9]. The absolute excess risk was small: roughly 11 additional reports per 1,000 patients per year. The analysis did not find a significant difference in muscle symptom rates between individual statins at equipotent doses.

Rhabdomyolysis, the most serious muscle complication, occurs in fewer than 1 in 10,000 statin-treated patients annually [10]. Neither rosuvastatin nor atorvastatin carries a meaningfully higher rhabdomyolysis rate than the other when used within approved dose ranges.

Hepatic and Renal Considerations

Both drugs can cause transaminase elevations, though clinically significant liver injury is rare. The FDA prescribing information for rosuvastatin includes a precaution for patients with active liver disease [10]. Rosuvastatin is contraindicated at the 40 mg dose in patients with unexplained persistent transaminase elevations.

One distinction: rosuvastatin is primarily excreted by the liver without extensive CYP450 metabolism, so about 10% of the parent drug appears in urine. Patients with severe renal impairment (CrCl <30 mL/min) require dose adjustment for rosuvastatin (starting at 5 mg, max 10 mg), while atorvastatin does not require renal dose adjustment [10].

Diabetes Risk

Both high-intensity statins modestly increase the risk of new-onset type 2 diabetes. A meta-analysis published in The Lancet (N=91,140 across 13 trials) found a 9% increased relative risk of diabetes with statin therapy [11]. JUPITER specifically reported a small but statistically significant increase in physician-reported diabetes with rosuvastatin (3.0% vs. 2.4% with placebo over 1.9 years) [4]. The cardiovascular benefit consistently outweighs the diabetes risk in patients who meet guideline criteria for statin therapy.

Drug Interactions

This is where the two statins differ most. The difference in metabolism creates distinct interaction profiles that matter in real-world prescribing.

Atorvastatin and CYP3A4

Atorvastatin is metabolized through the CYP3A4 enzyme system. Any drug that inhibits CYP3A4 can raise atorvastatin blood levels and increase side-effect risk. Common CYP3A4 inhibitors include clarithromycin, itraconazole, ketoconazole, HIV protease inhibitors (ritonavir, lopinavir), and even large quantities of grapefruit juice [12]. Patients taking these medications may need dose reductions or a switch to a different statin.

Rosuvastatin's Interaction Profile

Rosuvastatin bypasses CYP3A4 metabolism almost entirely. It is minimally metabolized by CYP2C9 and primarily eliminated as unchanged drug. This makes it a preferred statin for patients on CYP3A4-inhibiting medications [10]. Rosuvastatin does interact with cyclosporine (contraindicated in combination) and with certain anticoagulants (warfarin levels should be monitored at initiation).

Practical Takeaway for Polypharmacy

For patients taking multiple medications, especially those on HIV antiretroviral therapy, antifungal agents, or certain antibiotics, rosuvastatin often presents fewer interaction concerns. The 2018 ACC/AHA guideline specifically calls out statin-drug interactions as a factor to consider when selecting a statin [2]. "Clinicians should evaluate the potential for statin-drug interactions prior to initiating therapy," the guideline states.

Cost and Insurance Coverage

Both drugs are available as generics, but pricing is not identical.

Generic Pricing

Generic atorvastatin has been available since 2011, giving it a longer track record of generic price competition. Average retail cash prices for a 30-day supply of atorvastatin range from $4 to $15 at most US pharmacies. Generic rosuvastatin, available since 2016, typically costs $8 to $20 per month, though prices have converged significantly in recent years [13].

Formulary Placement

Most commercial insurers and Medicare Part D plans cover both generics on their lowest copay tier. Some plans place one statin on a preferred tier over the other based on rebate agreements. Checking your specific formulary before filling is the simplest way to minimize cost. Walmart, Costco, and several grocery-chain pharmacies include both generics in $4/$10 discount programs.

Brand-Name Costs

Brand-name Crestor and Lipitor are rarely dispensed now. If a prescriber writes for brand-only (which is uncommon), expect $300-$400/month without insurance. This is almost never necessary given generic bioequivalence.

Who Should Choose Rosuvastatin Over Atorvastatin (and Vice Versa)

Neither drug is universally superior. The 2018 ACC/AHA cholesterol guideline does not recommend one high-intensity statin over another [2]. Selection should be based on individual clinical factors.

Consider Rosuvastatin When

The patient takes CYP3A4-inhibiting medications (HIV protease inhibitors, azole antifungals, macrolide antibiotics). The patient needs maximum LDL reduction and prefers a lower pill dose (rosuvastatin 20 mg vs. Atorvastatin 40-80 mg for similar effect). The patient has a history of CYP3A4-mediated side effects on atorvastatin.

Consider Atorvastatin When

The patient has severe renal impairment (no dose adjustment needed). The patient has had a recent stroke or TIA (SPARCL data supports atorvastatin 80 mg specifically) [7]. Cost sensitivity is high and the local pharmacy prices atorvastatin lower. The patient is already stable on atorvastatin with good LDL response and no side effects. Switching statins for marginal LDL gains risks introducing new side effects without a clear clinical payoff.

When to Consider Switching

The ACC/AHA guideline recommends reassessing statin therapy if the patient does not achieve the expected LDL percentage reduction (50% or greater for high-intensity therapy) after 4-12 weeks, or if the patient develops intolerable side effects [2]. Before switching, confirm adherence. A 2019 analysis in the Journal of the American Heart Association found that nearly half of patients who "failed" statin therapy had adherence rates below 80% [14].

What the Guidelines Actually Say

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol makes no distinction between atorvastatin and rosuvastatin for patients who qualify for high-intensity statin therapy [2]. The four statin benefit groups (clinical ASCVD, primary severe hypercholesterolemia with LDL 190 mg/dL or greater, diabetes ages 40-75, and elevated 10-year ASCVD risk 7.5% or higher) all list "high-intensity statin" as the recommendation without naming a preferred agent.

European Guidance

The 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias similarly do not preferentially recommend one statin over another [15]. The European guidelines are more aggressive on LDL targets (below 55 mg/dL for very-high-risk patients), which may favor rosuvastatin's slightly greater potency in some cases, but the guideline text does not specify an agent.

AHA Scientific Statement on Statin Safety

A 2019 AHA scientific statement noted that "the benefits of statin therapy far outweigh the risks for patients for whom statins are recommended" and emphasized that statin intolerance is often overdiagnosed [14]. The statement recommends rechallenging with a different statin or lower dose before abandoning the drug class entirely.

Switching Between the Two Statins

If a prescriber decides to switch from one to the other, dose equivalency matters. The general conversion: rosuvastatin 5 mg approximates atorvastatin 10 mg, rosuvastatin 10 mg approximates atorvastatin 20 mg, rosuvastatin 20 mg approximates atorvastatin 40 mg, and rosuvastatin 40 mg approximates atorvastatin 80 mg [2].

Lipid panels should be rechecked 4-12 weeks after switching. There is no required washout period. Patients can transition directly from one to the other at the next scheduled dose.